Morgan “Caitlin” McKenna

Director, Office of Grant Support (OGS)

Phone: 718-430-3642 

Email: morgan.mckenna@einsteinmed.edu

Message from the Director


Hello,


The Office of Grant Support wishes you all a very happy holiday season! We hope you all have a wonderful time with family and friends as we prepare for 2025.


In this December edition of the newsletter, I will provide details on our institutional submissions, office updates, sponsor updates, internal forms changes, system updates and proposal reminders.


Application Breakdown


The Office of Grant Support has reviewed the submission data for 2024. Einstein application data from January – December 31st, 2024, includes 1200 applications (921 New, 43 Renewal, 202 Resubmission, 34 Supplement). The total cost request is $1,552,004,092. These applications were submitted by 60 Departments/Divisions across the institution. The funding breakdown: 50% Federal prime, 22% Federal and Non-Federal subcontracts, 21% Non-Federal prime, 5% Industry, 1% International Sponsors and >1% New York State.

Office Updates and Reminders


We are recruiting for a Senior Grant Specialist and a Grant Specialist. Come join our team!


Resource - Funding: OGS maintains an active license with SPINPlus portal. This portal has over 40,000 funding opportunities and allows investigators to set filters and receive notifications from the system of new field specific opportunities as they become available.


Reminder - Communication: Please ensure that communication and sponsor required clarifications route through OGS. As the Authorized Organization Representatives (AOR), we will review, provide feedback, and offer our concurrence for all direct sponsor communications.


Reminder – ProposalCentral: If you are submitting to a non-federal sponsor using ProposalCentral and you require institutional signature, you need to list the appropriate central office staff and provide edit access for the collection of signatures. All ProposalCentral full applications require an approved Cayuse record.


Reminder – Federal Applications: SF424 R&R page 1 “Person to be contacted on matters involving this application” list administrator information or Indranil Basu or Morgan McKenna. If you are submitting a DoD application list only OGS contact. SF424 R&R page 2 section for Authorized Representative please list Indranil Basu or Morgan McKenna. Applicant information should include Division as “Albert Einstein College of Medicine.”


Submission Policy Clarification: OGS requires the routing of proposals 8 business days prior to deadline for administrative documents. This includes the final budget, justification(s), Data Management and Sharing Plan (if applicable), biosketch of all key personnel, subcontract documents (performance site, biosketch of key persons, budget, and justification. If complete, you can also upload the Facilities and Other Resources, Equipment, Key Authentication, Vertebrate animal document and the Protection of Human Subjects and study record documents.


If you are collaborating with a foreign site(s), you are required to provide a signed letter of support for each site with the language listed on the supplemental form for OGS review.


We request the upload of final science 2 days prior to deadline.


Reminder - Routing: All Cayuse applications require full routing and budget approval prior to submission to sponsors.


Reminder – New Sponsors: If you plan to work with a new sponsor, it is important that OGS review contract and/or award terms. Please route language to OGS prior to submission.


Reminder (Holiday or Office Closure): OGS will have coverage for urgent signatures and application deadline support. Please be proactive and route applications and signature requests to OGS in advance.


Federal Sponsor Updates and Resources


NIH Update: Common Forms Adoption for Biographical Sketch and Current and Pending (Other Support) for all submissions on or after May 25th, 2025 (NOT-OD-24-163).


Data Management and Sharing Plan (DMSP) and Reporting: Effective 10/1/2024, NIH RPPR requires answers concerning the implementation of the DMSP. If there are changes to the plan, this needs to be communicated in the RPPR. If there are clarifications or requests for further information during review this will be required at JIT.


Data Management and Sharing Costs: Need to be assigned to the category of spending and identified clearly in the justification. If you submit a detailed RR budget, you will have the costs in the category (i.e., Personnel effort % calculation, equipment, Other direct cost). If you submit a modular budget, you will include Data Management and Sharing Cost on the Additional Narrative Justification.


Reminder for DMSP: OGS is not involved in the implementation of the DMSP. Please do not list OGS, RF, or any other central office on Element 6 of the plan, as this should be project personnel.


NIH: Peer Review – Simplified Review Framework for NIH Research Project Grant Applications (NOT-OD-24-010). This new framework and structure will begin with submission for due dates on or after January 25th, 2025. Information concerning the framework is included in updated NOFOs. Resources for Simplified Review Framework webinar and overview of changes are available here.


NIH – Clarification: NIH does not allow for overlapping or duplicative funding. Please read the extramural article on research integrity. The link can be found here.


NIH –Grant review using Artificial intelligence and other digital technologies to enhance grant management operations. Please read the article on this link.


Upcoming Form and System updates: The required Cayuse Supplemental form is under review. Several units and administrators have contributed suggestions, which will be incorporated. This new form 5.1 will be circulated for use when the review is complete.


Reminder – Early Approval: Cayuse has added a required field to the proposal in SP (Early Approval /Submission Request). If you require an early review, select Yes, and enter the date in the text box. If you do not require an early review, select No. Please ensure your review request is consistent with the submission policy and provides reasonable turnaround time for OGS review. All documents should be complete and correct to ensure an early review can be completed on the requested date.


Training: Cayuse training will continue to be available monthly by invitation. Please contact OGS to request inclusion (OGS@einsteinmed.edu). OGS is creating training in specific areas including Other Support, Common Forms, and Budget Development. Training will be available in first quarter of 2025. More information to come.


Please continue to reach out to OGS for all your research administrative related inquiries. We look forward to continuing to provide a high level of support for your applications as well as clear updates on sponsor’s requirements and guidance to maximize funding success!


Sincerely,

M. Caitlin McKenna

Important links and documents

I) Einstein's institutional information, including DUNS#, UEI#, EIN#, New IPF#, Congressional District, and more, can be accessed by clicking here.


II) The Einstein Pre-Award Forms (which include Cayuse Supplemental 5.0, eRA Commons account request, Cayuse user request, New Sponsor, PI certification, SOI lead and non-lead, and more) are available for download from this page.


III) On October 1, 2024, the automated email from eRA that requested Just-in-Time information for an application was discontinued. This email was sent from era-notify@mail.nih.gov to include all applications with an overall impact score of 30 or less.


This email did not reflect the intent of an NIH Institute/Center (IC) to fund an application, and could be misconstrued by an applicant as an indication that the application will be funded. Hence, it was retired (see a sample email notification and NIH Guide Notice NOT-OD-24-165).


The grants management staff will continue to send the official email requesting Just-in-Time information from the awarding IC to the principal investigator (PI) of the application and the signing officials (SOs) associated with the organization.



NIH Updates

Weekly NIH Funding Opportunities and Notices



Please click on the dates below to view weekly NIH notices and funding opportunities: December 06, December 13, December 20, and December 27.

Timeline for Assignment, Review, and Council


Your application is evaluated by NIH and assigned to an institute. The peer review process occurs four or five months after the NIH deadline. The majority of applications are submitted to the full Council meeting about seven months after the due date.

Click here to view the graphic that marks this phase of the process.

NOT-OD-25-040: NIH Requires Mandatory Use of the eRA Prior Approval Module for the Submission of Prior Approval Requests for all SBIR and STTR Awards Beginning January 27, 2025.

Starting on January 27, 2025, NIH will require the submission of all prior approval requests for SBIR and STTR awards via the eRA Commons Prior Approval Module. This change will continue to aid NIH in moving towards electronic submission of prior approval requests. A Signing Official (SO) for the recipient organization must initiate and submit all prior approval requests.

Read More

NOT-OD-25-044: Reminder of Updates to NIH Training Grant Application Data Tables for Application Due Dates on or After January 25, 2025

This notice serves as a reminder regarding updates to the training data tables required for the NIH Institutional Training Program application. The commencement of these changes occurs with submissions due on or after January 25, 2025. These changes aim to reduce the burden on applicants and reviewers and encourage consistent information collection across training programs.

Read More

NOT-CA-25-013: Notice of the Discontinuation of NCI's Participation in PA-23-262 "Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32)

Effective December 10th, 2024, this Notice informs prospective F32 individual postdoctoral fellow applicants that the National Cancer Institute (NCI) will discontinue their participation in the Notice of Funding Opportunity (NOFO) PA-23-262 "Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32)", or any subsequent reissues of the NOFO. Resubmissions and applications related to PA-23-262 or NOFO reissues after December 10, 2024 will not be accepted by NCI.

Read More

NOT-OD-25-048: Supplemental Guidance to the 2024 NIH Public Access Policy: Publication Costs

It is acknowledged by NIH that some peer-reviewed publishing paths may lead to publication expenses, such as article processing charges (APCs). Publication costs are allowable when they comply with the existing NIH cost principles (Grants Policy Statement (GPS) 7.2 and GPS 7.9.1 (Publication and Printing Costs)). The cost principles define when costs should be classified as direct versus indirect costs, and they define charges and fees that are permissible under the outlined conditions.

This Guidance is intended to help funded authors and institutions understand what costs are allowable and reasonable under the NIH Public Access Policy.

Read More

NOT-OD-25-026: Reminder: FORMS-I Grant Application Forms and Instructions Must be Used for Due Dates On or After January 25, 2025

Reminder: The FORMS-I Grant application forms and instructions must be used for due dates on or after January 25, 2025. Early submission is encouraged for applicants to have time to work through any unforeseen issues.

Read More

NOT-OD-25-035: Reminder that Multiple Changes Affecting Extramural Applications and Review are Coming for Application Due Dates on or After January 25, 2025

This notice is intended to remind the research and research training community of multiple changes that are affecting the application and peer review processes impacting grant applications submitted for due dates on or after January 25, 2025, and on or after May 25, 2025.

Read More

NOT-OD-24-157: Implementation Update for Data Management and Access Practices Under the Genomic Data Sharing Policy

On January 25, 2025, the NIH is going to update two practices under the NIH Genomic Data Sharing (GDS) Policy to continue to promote responsible data management and access. The goal of these changes is to make sure that GDS Policy implementation keeps up with the changing practices of collecting, sharing, and using controlled-access human genomic data, which includes - (1) modernizing security standards provided in the NIH Security Best Practices for Controlled-Access Data Subject to the NIH Genomic Data Sharing (GDS) Policy and (2) establishing minimum expectations for developers' access to controlled-access data.

Read More

NOT-GM-24-054: Notice of Change to Reduce the Required Effort Level for Program Directors/Principal Investigators in PAR-22-180 Maximizing Investigators' Research Award (R35 - Clinical Trial Optional)

The purpose of this notice is to let investigators know that the minimum research effort level required for the Maximizing Investigators' Research Award (MIRA) has been decreased for both established and new investigators (EI/NIs), effective October 1, 2024.


PDs/PIs that have been currently funded through PAR-22-180 or earlier versions of this MIRA NOFO must devote at least 45% of their total research effort to the MIRA through the remainder of the grant project period. No prior approval is required for an effort reduction as long as it does not exceed the prior approval threshold for a change in the status of the PD/PI.

Read More

FY25 Pre-announcement released for Epilepsy

The Epilepsy Research Program (ERP) released a pre-announcement for the following funding opportunities:



·       Idea Development Award

·       Leveraging Research Award

·       Research Partnership Award

·       Virtual Post-Traumatic Epilepsy Research Center Faculty Award


Visit this page to view the pre-announcement.

Read More

Non-Federal Funding Opportunities

CRI Lloyd J. Old STAR Program | Cancer Research Institute

Long-term funding for mid-career scientists pursuing high-risk, high-reward research at the forefront of discovery and innovation in cancer immunotherapy. CRI STARs (Scientists TAking Risks) are expected to be the future leaders in the field. The Lloyd J. Old STAR program provides up to $1.25 million over a five-year period to tenure-track assistant professors (minimum of three years) and associate professors (maximum of three years).


The application is due by January 15, 2025.


Click here to find the details about this funding opportunity.

Read More

Victoria’s Secret Global Fund for Women’s Cancers Rising Innovator Research Grants, in Partnership with Pelotonia and the AACR

Female associate professors are invited to apply for the Victoria’s Secret Global Fund for Women’s Cancers Rising Innovator Research Grants, in collaboration with Pelotonia and the AACR. These $700,000, three-year grants support research on breast or gynecologic cancer, with a focus on health disparities encouraged.


Eligible projects can span basic, translational, clinical, or population sciences and must be directly relevant to advancing the understanding, prevention, early detection, diagnosis, or treatment of breast and gynecologic cancers.


The Letter of Intent deadline is January 23.

Read More

Arthritis Research Grants | Arthritis National Research Foundation

The ANRF Psoriatic Arthritis Grant is a unique funding opportunity designed to catalyze innovation in Psoriatic Arthritis (PsA) research. With funding of $250,000 for two years, generously supported by Johnson & Johnson Innovative Medicine, this grant offers an unparalleled opportunity to advance our collective understanding of PsA and improve outcomes for patients worldwide. Applications are due by January 24th, 2025,

Learn more about the grant, eligibility, and how to apply here.

Read More

Application Resources:

Beginning on July 1, 2024, only AHA Professional Members will be permitted to submit required pre-proposals, unless noted in the request for proposals.

Research Supplement to Promote Diversity in Science

Proposal deadline: Thursday, February 6, 2025

To enable current AHA awardees to identify and serve as mentors for predoctoral and postdoctoral fellows from underrepresented groups in science and medicine.

Read More

CFF Physician Training & Career Development Programs RFAs

Clinical Fellowships, LeRoy Matthews Award, and the Harry Shwachman Award:


These programs aim to attract, develop, and retain exceptional clinicians and investigators into cystic fibrosis care and research to address the evolving needs of the CF community.


Applications to all Physician Training and Career Development Programs must be submitted online at awards.cff.org by February 26, 2025.


The CF Foundation will host a webinar to walk through what makes a good application with a live question and answer session at 2:00 pm ET January 14, 2025. Register here. For questions, please contact Elizabeth Yu (eyu@cff.org).  

Read More

Lupus Foundation of America's 2025 Grant Opportunities

Grant Funding Opportunities are available for:

Medical and Graduate Students

Clinical and Postdoctoral Fellows

Established investigators conducting pediatric lupus research

Investigators based in Canada

Application Deadline: February 27th, 2025

Grant Amounts: $4,000-$140,000

To learn more about the application process, eligibility criteria, and specific focus areas, please visit the Lupus Foundation of America's website. You will find comprehensive guidelines and details on how to submit your proposal successfully. Please email crump@lupus.org with any questions.

Read More

Limited submission

RFP for Ono Pharma Foundation Breakthrough Science Initiative Award

The Ono Pharma Foundation is offering a Breakthrough Science Initiative Award. Einstein may submit two applications. From among the internal applications, the Einstein Awards Committee will select two nominees for the award.

 

If you are interested in applying, please read the information and follow the instructions below.

 

Internal Deadline: January 3, 2025

Foundation LOI Deadline: February 14, 2025

Amount: $1,035,000/3 years (includes 15% IDC)

About: The Ono Initiative supports creative research conducted by emerging Chemical Biologists in search of new discoveries, solutions, and the development of high-impact science. The goals are to identify and develop innovative research proposals and results that could lead to the development of treatments for patients; support academic research and the career development of both early-career and established scientists; and build strong relationships within the community to lead to transformative research aligned with Ono Initiative's interest. For 2025, subjects of interest include: Modulating interactome and cell/tissue crosstalk; Manipulating biomolecular condensates and protein quality control systems; Deep understanding and emerging applications of chemical glycobiology; New concepts of drug delivery and localization to tissue/cell/organelle; and Understanding and leveraging allostery in biology.

 

Eligibility: MD and/or PhD; new applicant or project; 15 years or less since independent academic position; not engaged with *Ono Pharmaceutical Co. or Foundation; new idea rather than amplify current work; not a healthcare professional (MD w/o active state medical license is eligible); serving on healthcare formulary or similar committee not eligible.


Link: Ono Initiative for further information or contact Audrey McInerney (amcinerney@montefiore.org).


Instructions: Please email your c.v., including bibliography and other support; a one-page concept paper on the attached template; and the attached Candidate Profile Form filled in with your information, to Audrey McInerney (amcinerney@montefiore.org) by January 3 at 5:00 pm.


 *Ono Pharmaceutical Co., Ltd., based in Japan, is a global healthcare company committed to delivering new innovative drugs to patients. Ono Pharma USA Inc., a fully owned subsidiary based in Cambridge, MA, founded the independent Ono Pharma Foundation. The Foundation was established to support academic research in relevant scientific fields, which have the potential of making significant impact on therapeutic approaches to disease.

Read More

Please note the OGS email address: OGS@einsteinmed.edu